Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:47 PM
Ignite Modification Date:
2025-12-24 @ 10:47 PM
NCT ID:
NCT00326469
Eligibility Criteria:
Inclusion Criteria:
* patients with histopathologic diagnosis of well-differentiated neuroendocrine tumour or carcinoma according to WHO classification
* patients who, according to RECIST criteria (Response Evaluation Criteria in Solid Tumours) present measurable disease
* patients with progressive disease in the previous 6 months before their inclusion in the study
* patients with positive IN111 octreotide scintigraphy
Exclusion Criteria:
* patients with surgically removable localised disease
* patients with progressive disease in the first six months of being diagnosed
* patients with intestinal obstruction due to a carcinoid tumour
* patients who have received treatment with somatostatin analogues during the 6 months before being included in the study
* patients who have received treatment with radiotherapy, chemotherapy or interferon 4 weeks before being included in the study, or planned to receive these during the study
* patients who have received treatment with liver artery embolisation or radiopharmaceuticals (endoradiotherapy) 12 weeks before being included in the study, or planned during the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00326469
Study Brief:
Protocol Section:
NCT00326469